A Biopharma Company which is clinical-stage and develops oral minute molecule therapies to treat the diseases in the zone of oncology, lysosomal storage disorders, and Fibrosis; Inventiva, made an announcement today regarding the establishment of its Scientific Advisory Board (SAB) as part of its attempt for providing scientific review externally and advanced level advice to the management of the company with respect to its Research and Development activities and the portfolio of products.
The Scientific Advisory Board will be covering the primary areas of the Inventiva’s research and development with a special focus on the oncology, on non-alcoholic steatohepatitis, as well as, on the mucopolysaccharidoses. To be precise, it will be supporting the management of the company with regards to the clinical and the preclinical aspects of the development of the Inventiva’s programs and its international science policy which includes the field of research, objectives, collaborations & associations, and the access of the market.
The former Director of the Board of Directors of Inventiva; Jean Louis Junien who is also the chair and a Senior Pharma Executive who has a vast and far-reaching experience in the industry, the Senior Advisory Board will be bringing together the skills of the independent global scientists, as well as, the clinicians in those fields which are mentioned above. There is a need for an extra member in the Senior Advisor Board who would have specialization in rare diseases in order to support the establishment of the odiparcil in the MPS shortly. The very first 2 meetings have been scheduled already for the SAB and their main focus will be on the oncology and the NASH.
The CSO & Co-founder of Inventiva, Pierre Broqua passed the following statement: “The establishment of SAB is a vital initiative towards our future development as it will give a boost & security to our discovery programs and also give validation to Research & Developmental choices.”